Clinical Trials Browser

Phase 3 × taletrectinib × 90 days × Clear all

NCT07154706 2026-02-11

Phase 3 Study of Taletrectinib vs Placebo as an Adjuvant Therapy in ROS1 Positive NSCLC (TRUST-IV)

Phase 3 Recruiting

Carcinoma, Non-Small-Cell Lung